title: Role of serum high mobility group box 1 in hematological malignancies complicated with systemic inflammatory response syndrome and effect of recombinant thrombomodulin.
abstract: High mobility group box 1 (HMGB1) mediates inflammation. We investigated the role of serum HMGB1 in 54 patients with hematological malignancies with and without systemic inflammatory response syndrome (SIRS). There was no difference between groups 1 (complete remission of hematological disease: n = 13) and 2 (no remission: n = 16) in serum HMGB1 levels. However, those of group 3 (complicated by SIRS: n = 25) were significantly higher (vs. group 1: p < 0.001 and vs. group 2: p = 0.008, respectively). Seventeen patients in group 3 also developed disseminated intravascular coagulation and received recombinant human thrombomodulin (rhTM). Thirteen of those with SIRS improved, and serum HMGB1 levels significantly decreased (p = 0.047). Seven patients in group 3 who died within 28 days of SIRS onset had significantly higher serum HMGB1 levels than the survivors (p = 0.016). The anti-HMGB1 properties of rhTM might be useful therapy if serum HMGB1 is associated with the development of SIRS in the presence of hematological malignancies.
authors: Division of Hematology and Oncology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan. yasu-ino@marianna-u.ac.jp
authors: Yasuyuki
authors: Y
authors: Inoue
authors: Tasuku
authors: T
authors: Saito
authors: Kohei
authors: K
authors: Ogawa
authors: Yuji
authors: Y
authors: Nishio
authors: Shigeki
authors: S
authors: Kosugi
authors: Yoshinori
authors: Y
authors: Suzuki
authors: Hirotaka
authors: H
authors: Sakai
authors: Masayuki
authors: M
authors: Kato
authors: Masatomo
authors: M
authors: Takahashi
authors: Ikuo
authors: I
authors: Miura
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D024243:HMGB1 Protein / Q000097:blood*; D019337:Hematologic Neoplasms / Q000097:blood* / Q000150:complications* / Q000188:drug therapy / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D012372:ROC Curve; D011994:Recombinant Proteins / Q000627:therapeutic use; D018746:Systemic Inflammatory Response Syndrome / Q000097:blood* / Q000150:complications* / Q000188:drug therapy; D018180:Thrombomodulin / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D024243:HMGB1 Protein; D011994:Recombinant Proteins; D018180:Thrombomodulin